AbbVie Bought The Factory In Singapore
AbbVie announced the acquisition of biopharmaceutical production in Singapore Technology Park Tuas Biomedical. The purchase of a factory for the production of pharmaceutical substances on the basis of low-milecule substances will allow the company to boost production of immunological and oncological drugs.
The production platform in Singapore was the first factory in Asia AbbVie. It occupies 120 thousand sq. meters of the enterprise 's production facilities and auxiliary facilities. It is expected that it will reach the full capacity in 2016.
Earlier this year, AbbVie announced its intention to build a factory for the production of active substances in Singapore. This production platform should start in 2019.
- AbbVie Can Abandon The Acquisition Of Shire
- AbbVie Paid Shire 1,6 Billion For Failed Acquistion
- Russian Scientists Are Developing New Anti-Influenza Drug